NeuroMetrix, Inc. Warrants
NUROW
NUROW was delisted on the 26th of May, 2020.
2 hedge funds and large institutions have $0 invested in NeuroMetrix, Inc. Warrants in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less capital invested
Capital invested by funds: $2K → $0 (-$2K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | +$2 | +10 | +0.5% |
|
NUROW Hedge Fund Activity: Q3 2019 in Review
2 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in NeuroMetrix, Inc. Warrants (NUROW) for Q3 2019, worth a combined $0 — down 100% from $2K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NUROW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $2.
- 2 institutional investors held NeuroMetrix, Inc. Warrants (NUROW) as of Q3 2019, down from 3 in Q2 2019.
- Funds reported $0 of NeuroMetrix, Inc. Warrants stock for Q3 2019, down 100% quarter-over-quarter.
- 0 funds opened new NeuroMetrix, Inc. Warrants positions in Q3 2019 and 1 closed out, a net change of -1 holder.
- The largest NeuroMetrix, Inc. Warrants buyer in Q3 2019 was UBS Group, an estimated $2 added.
Based on aggregated 13F filings for Q3 2019.